LataMed AI is trading 6.23% higher at $0.51 as investors continue reacting to its August 19 announcement that its mobile healthcare application entered final testing.
- Management is preparing Apple App Store and Google Play submissions in the coming weeks, subject to platform review and technical requirements.
- No separate August 25 announcement or confirmed trading-volume catalyst was identified.
- Broader markets are modestly higher, but the app-development milestone remains the clearest identified driver.